HealthDay News — For patients with sentinel lymph node (SLN)-positive melanoma, fewer patients are undergoing completion lymph node dissection (CLND) and more are receiving adjuvant systemic therapy, according to study published online Jan. 27 in the Annals of Surgery.

Kristy K. Broman, M.D., M.P.H., from Moffitt Cancer Center in Tampa, Florida, and colleagues examined overall trends and center-level variation in utilization of CLND and adjuvant systemic therapy in an international cohort study at 21 centers involving adults with SLN-positive melanoma and negative distant staging from July 2017 to July 2019.

The researchers found that performance of CLND decreased from 28 to 8 percent among 1,109 patients, and use of adjuvant systemic therapy increased from 29 to 60 percent. The most influential factors for both CLND and adjuvant systemic therapy were nodal tumor size, stage, and location of treating center. Management of stage IIIA patients varied notably among treating centers, as did use of CLND with adjuvant systemic therapy versus nodal observation alone for similar-risk patients.


Continue Reading

“These changes in practice began prior to the publication of landmark trials of nodal observation and adjuvant immunotherapy and targeted therapy but accelerated dramatically at the included melanoma referral centers over a two-year time period postpublication,” the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)